Ann: H1 2023 Preclinical and Clinical Programs Update, page-89

CR a possibility as part of RAC wanting to provide outsized returns to shareholders rather than lending shares & cheaply selling to banking mates, although at one point further investment like Merchant Opportunities Fund and larger needed as many are tapped out, myself included after buying the last few months.

I foresee announcements of collaborations, then partnerships that involve sharing of expertise & access to experts/facilities/marketing, followed by capital, followed by upfront $$ then milestone payments. This should re-rate us a push well past the ATH by multiples based on other biotechs reaching these stages, then eventually hope for a biding war and buyout, cancer patients worldwide being treated and cured. RAC holders rejoice & patience rewarded with $$$$$.

Personally expecting more connections between RAC & DCB's network in terms of new team & partners, as well as collaborators & partnerships